PharmaFocus Today – Page 49 – media

CanSino accelerates global deployment of dual vaccines

CanSino’s independently developed 13-valent pneumococcal polysaccharide conjugate vaccine PCV13i and Asia’s first quadrivalent meningococcal polysaccharide conjugate vaccine MCV4 were shipped to the domestic and overseas markets respectively. CanSino Biologics’ independently developed 13-valent pneumococcal polysaccharide conjugate vaccine, Upexin®, was officially approved by the National Medical Products Administration in June of this year. It is China’s first pneumococcal polysaccharide conjugate vaccine to utilize a dual vector consisting of an avirulent mutant of diphtheria toxin (CRM197) and tetanus toxoid (TT). This vaccine provides enhanced protection against the four serotypes (19F, 19A, 7F, and 3) that carry the heaviest burden of pneumococcal disease in children in China. It is reported that by 2026, Upexin® will expand its reach into the domestic market, with overseas expansion also in the works. When Youpexin® was shipped domestically, Asia’s first ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 vector) Manhaixin® also departed from Tianjin and was sent to Indonesia. ...
- Source: drugdu
- 137
- October 9, 2025
Subsidiary’s chorionic follicle-stimulating hormone αN02 injection approved for marketing in China

Changchun High-techChangchun High-Tech Industry (Group) Co., Ltd. (hereinafter referred to as ” Changchun High-Tech “) issued an announcement stating that its subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as “Jinsai Pharmaceutical”) recently received the “Drug Registration Certificate” approved and issued by the State Food and Drug Administration. Its application for the choriofollicle-stimulating hormone αN02 injection has been approved for marketing in China. The approved indication is for use in combination with a gonadotropin-releasing hormone antagonist for controlled ovarian stimulation to induce the development of multiple follicles. A single subcutaneous injection of choriofollicle-stimulating hormone αN02 injection (Jinsaijia®) replaces the 7-day use of follicle-stimulating hormone for assisted reproduction .Ovarian stimulation therapy brings new options. In recent years, demand for assisted reproductive technology has continued to grow. In 2015, Jinsai Pharmaceutical launched the first domestically developed recombinant human follicle-stimulating hormone (RFH) for injection (Jinsai Heng®). This short-acting formulation, administered daily, was ...
- Source: drugdu
- 167
- October 9, 2025
Pfizer and the U.S. government reached a drug pricing agreement to bring U.S. drug prices in line with other developed countries

After the U.S. stock market opened on Tuesday, Pfizer,　　which has been deeply affected by the uncertainty of U.S. pharmaceutical policies this year,The company’s stock price rose by over 4% at one point. Multiple sources indicate that Pfizer CEO Albert Bourla will visit the White House later on Tuesday to announce drug pricing policies and a $70 billion domestic investment plan with Trump. ( Pfizer daily chart, Source: TradingView) In addition to Pfizer, many large pharmaceutical companies also rose .Bristol-Myers Squibb rose nearly 3%.Up 2%, AmgenUp 1%. If the news is true, Pfizer has resolved at least two policy uncertainties : US President Trump once wrote to Pfizer and 16 other pharmaceutical companies asking for price cuts, and demanded that prices in the United States should not be more expensive than those in developed countries such as Europe (the “most favored nation” policy); Trump also announced tariffs on branded drugs last ...
- Source: drugdu
- 136
- October 9, 2025
Another pharmaceutical giant terminates AAV gene therapy business

According to foreign media reports, Biogen has terminated all gene therapy projects based on adeno-associated virus (AAV) capsids. In fact, Biogen deprioritized gene therapy as early as 2023. Now, as part of its ongoing capital allocation strategy, the company will completely abandon AAV technology. Biogen is a biotechnology company with deep expertise in rare and genetic diseases. The company said it will continue to focus on this area in the future and concentrate its resources on advanced therapies and drugs that have greater potential and are more likely to bring better therapeutic effects to patients. Most of the team members who were previously responsible for AAV vector research and development have been reassigned to other positions within the company, but a small number of people are still facing layoffs, involving R&D, operations, technology and other positions. Biogen is not the first company to abandon AAV technology. AAV (adeno-associated virus) is ...
- Source: drugdu
- 182
- October 9, 2025
Signed a licensing agreement with Glenmark Specialty for the Ruikang trastuzumab project, with revenue potentially exceeding US$1.1 billion.

Hengrui Medicine recently announced the signing of a licensing agreement with Glenmark Specialty SA for the Ruikang Trastuzumab project. The agreement provides for a paid license to Glenmark Specialty SA for the company’s innovative Class 1 drug, Ruikang Trastuzumab (SHR-A1811), for which the company holds independent intellectual property rights. Ruikang Trastuzumab is an antibody-drug conjugate (ADC) independently developed by Hengrui that targets HER2. It binds to and is internalized by HER2-expressing tumor cells. Within the tumor cell lysosome, trastuzumab releases a toxin through proteolytic cleavage, inducing cell cycle arrest and ultimately apoptosis. The released toxin is highly permeable, exerting a bystander effect and further enhancing anti-tumor efficacy. The company’s Ruikang Trastuzumab was approved for marketing in China in May 2025. It is indicated for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have HER2 (ERBB2) activating mutations and have previously received ...
- Source: drugdu
- 184
- October 9, 2025
The application for marketing authorization of trivalent influenza virus split vaccine has been accepted

People’s Finance News reported on September 24 that Kangtai Biological(300601) announced on September 24 that the influenza vaccine developed by the companyThe application for marketing authorization of the viral split vaccine recently received an acceptance notice issued by the National Medical Products Administration. The influenza virus split vaccine 　　whose marketing authorization application was accepted this time is a trivalent influenza vaccine. Together with the quadrivalent influenza virus split vaccine that the company has applied for production registration, the quadrivalent influenza virus split vaccine (for people aged 6-35 months) that has been approved for clinical trials, the quadrivalent influenza virus split vaccine (MDCK cells) and the trivalent influenza virus split vaccine (MDCK cells), they constitute an influenza vaccine series covering all age groups. https://finance.eastmoney.com/a/202509243522587919.html
- Source: drugdu
- 120
- October 8, 2025
Walvax Biopharma’s vaccine receives Jordanian Drug Registration Certificate, marking a key step forward in its Middle East market expansion.

　　Shanghai Securities News China SecuritiesNet News (Reporter Sun Zhong) Walvax BioAn announcement on the 29th stated that the 13-valent pneumococcal polysaccharide conjugate vaccine produced by its subsidiary Yuxi Walvax recently received a “Drug Registration Certificate” issued by the Jordan Food and Drug Administration. 　　The Yuxi Walvax 13-valent pneumococcal polysaccharide conjugate vaccine is mainly suitable for vaccination of infants and children aged 6 weeks to 5 years (before the age of 6 years). It is used to prevent infectious diseases caused by the 13 serotypes of pneumococcus contained in this vaccine (type 1, type 3, type 4, type 5, type 6A, type 6B, type 7F, type 9V, type 14, type 18C, type 19A, type 19F and type 23F). The vaccine was approved for sale in China in 2020. 　　Currently, pneumococcal infection remains one of the leading causes of death in children under five worldwide. In Jordan, this infection also poses a ...
- Source: drugdu
- 150
- October 8, 2025
Zhifei Bio’s independent product, influenza virus split vaccine, has obtained a drug registration certificate

　　Zhifei BioinfluenzaThe vaccine matrix has added another blockbuster product. The company announced on the evening of September 29 that the influenza virus split vaccine (referred to as “trivalent influenza vaccine”; registration category: preventive biological product) recently developed by its wholly-owned subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.) Obtain the “Drug Registration Certificate” issued by the State Food and Drug Administration. 　　Influenza is an acute respiratory infectious disease caused by the influenza virus that can cause widespread epidemics. It is highly contagious and can cause complications such as pneumonia, bronchitis, and myocarditis. It can aggravate underlying conditions in high-risk groups such as the elderly and the frail, increasing the disease burden and endangering human health. Flu vaccination is the most economical and effective measure to prevent influenza illness and influenza outbreaks. The trivalent influenza vaccine developed by Zhifei Longcoma is suitable for people aged three years and older to prevent infectious ...
- Source: drugdu
- 143
- October 8, 2025
Antihypertensive and lipid-lowering drugs show efficacy against steatotic liver disease

Metabolic dysfunction-associated steatotic liver disease is the most common liver disease in the world, affecting about one third of the adult population. This disorder is characterized by the accumulation of fat in liver cells, which has severe liver consequences and is also associated with a high mortality rate from cardiovascular disease. Now, a University of Barcelona study published in the journal Pharmacological Research shows that pemafibrate and telmisartan, two drugs already approved for other conditions, effectively reduce fat accumulation in laboratory animal models of metabolic liver disease. Furthermore, the study suggests that this combination of drugs may help to reduce both liver involvement and associated cardiovascular complications. These results open the door to the development of safer and more effective treatments for this disease, for which current therapeutic options are very limited. The study has been carried out by a team led by Marta Alegret, professor at the ...
- Source: drugdu
- 221
- October 7, 2025
Large-scale analysis offers insights into sporadic nature of chikungunya virus outbreaks

While the virus is common in tropical and subtropical regions, including Asia, Africa and South America, public health officials have been tracking reported infections in Europe and, in September, a confirmed case in Long Island, New York. Outbreaks of chikungunya have prompted the Centers for Disease Control to issue health notices to travelers bound for Bangladesh; Cuba; Guangdong Province, China; Kenya; Madagascar; Somalia; and Sri Lanka. In Guangdong Province, an”unprecedented”outbreak recently prompted government officials in China to mandate quarantines for anyone suspected of being infected by the virus, spraying individuals with mosquito repellent and spraying impacted buildings and other areas with insecticide. In a new study, published in Science Advances, researchers at the University of Notre Dame analyzed more than 80 outbreaks of chikungunya virus to improve prediction of future outbreaks and inform vaccine trial development. “Chikungunya outbreaks are unpredictable in both size and severity,”said Alex ...
- Source: drugdu
- 176
- October 7, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.